Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 521 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... December 17, 2025 For Women with Breast Cancer, Regular Exercise May Improve Survival May 15, 2020 Can the New “Omics” on the Block Find Liver Cancer in... May 15, 2023 The RAD51-IF Test Is Feasible for Assessment of the Functional Status... May 7, 2021 Load more HOT NEWS Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... When Ovarian Cancer Returns, Surgery May Be a Good Choice for... EMA Recommends Extension of Indications for Niraparib Efficacy, Safety, and Translational Data from Durvalumab Plus Ceralasertib in Advanced/Metastatic...
